Publications by authors named "Pujol-Montcusi J"
Background: Moderate-to-severe atopic dermatitis (AD) can be difficult to manage in paediatric patients, and there are few licensed treatments available for this age group. Dupilumab is approved for the treatment of AD in children older than 6 months.
Objectives: To assess the effectiveness and safety of dupilumab in a real-world cohort of paediatric patients with AD in Spain.
Detecting the association of genetic variants to the response of biological therapy represents an important advance in developing a personalized therapy. The aim of this work was to study the association of polymorphisms with an optimal response to tildrakizumab in patients with psoriasis in a real-life clinical practice. Ninety patients with plaque psoriasis recruited from-Spanish hospitals receiving tildrakizumab for at least 24 weeks were genotyped for 180 polymorphisms.
View Article and Find Full Text PDFBackground: Biological therapy dose modification is a common practice in the long-term treatment of plaque psoriasis.
Objective: The objective of the study was to determine prevalence, characteristics of patients, effectiveness, treatment survival of secukinumab dose reduction (SEC-DR) strategy and assess its safety and cost implications.
Methods: A retrospective, observational, multicenter cohort study was conducted in patients with plaque psoriasis treated with secukinumab and up to 2 years of follow-up.
Background: Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation.
Objective: To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting.
Methods: We studied 180 SNPs in patients with moderate-to-severe plaque psoriasis recruited from 15 Spanish hospitals.
Extramammary Paget disease (EMPD) is a rare skin tumor that manifests as poorly delimited lesions located mainly in genital area. Prognosis correlates with thickness and dermal invasion. The gold standard for diagnosis is the histopathological study of a biopsy.
View Article and Find Full Text PDFThe aim of the study was to assess the long-term effectiveness and safety of secukinumab in Spanish patients with moderate-to-severe psoriasis in a daily practice setting. Nationwide multicenter, observational, retrospective, non-interventional, single-cohort study including patients who initiated treatment with secukinumab in daily clinical practice conditions. Subjects were followed for a minimum of 3 months and a maximum of 24 months.
View Article and Find Full Text PDFArticle Synopsis
- * The study was conducted as a retrospective, observational, open-label cohort analysis of 238 patients, evaluating various QoL metrics such as the Dermatology Life Quality Index over 24 months.
- * Results showed that secukinumab treatment led to a notable improvement in QoL, particularly in patients new to biological therapies, with a strong correlation between improvements in quality of life and skin clearance over time.
Article Synopsis
- The study aimed to analyze the short- and long-term survival rates of secukinumab (SEC) in treating psoriasis, focusing on predictive factors for treatment continuation.
- Data were collected from 384 patients over two years, revealing cumulative survival rates of 97.1% at 6 months and 74.3% at 24 months.
- Factors such as obesity and previous biological therapy experience were linked to early discontinuation, while having psoriatic arthritis was associated with longer treatment duration.
Background: Phototherapy is a treatment option for atopic dermatitis recommended by several guidelines.
Objective: To perform a systematic review of the efficacy of different modalities of phototherapy and photochemotherapy in moderate to severe atopic dermatitis.
Material And Methods: We considered all randomized clinical trials (RCTs) performed in patients with atopic dermatitis, and accepted all outcome measures.
Background: Bromo-3-chloro-5,5-dimethylhydantoin (BCDMH) is a chemical used as a disinfectant for recreational water. BCDMH was described as being responsible for an epidemic of irritant contact dermatitis in the UK (1983), and its sensitizing capacity was also discussed.
Objectives: The aim of this study was to assess whether BCDMH used to disinfect swimming pools and spas can cause allergic contact dermatitis among its users.